文献速递造血干细胞移植与细胞治疗

供者年龄与供者巨细胞病毒血清状态对亲缘供者异基因造血干细胞移植后结局的影响

Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation.
PubMed 文献 · Am J Hematol · 2025-03-12

本研究纳入1013例巨细胞病毒(CMV)血清阴性的接受者,供者CMV血清阳性318例、阴性695例,移植类型包括HLA相合同胞供者及单倍体供者。多种常规与机器学习分析显示,供者CMV血清阳性与总生存和无病生存显著较差相关,主要由非复发死亡率增加驱动;供者年龄较大仅在部分模型中与结局相关且效应量小。作者认为优先选择CMV血清阴性供者可能与改善结局相关,需进一步研究验证。

要点

  • 在CMV血清阴性接受者中,供者CMV血清阳性与总生存和无病生存显著较差相关。
  • 供者CMV血清阳性者非复发死亡率约升高50%-60%(Cox模型)。
  • 供者年龄较大在部分模型中与总生存和无病生存相关,效应量小(Cox模型约每年风险增加1%)。

核心结论

  • 研究提示,在CMV血清阴性接受者中优先选择CMV血清阴性供者可能与改善结局相关。
  • 供者CMV血清阳性与总生存和无病生存显著较差相关,主要由非复发死亡率增加驱动。
  • 供者年龄较大仅在部分模型中与总生存和无病生存有统计学显著关联,效应量小。
  • 作者指出需进一步研究验证这些发现并探索潜在机制。

研究设计与样本

  • 研究纳入1013例CMV血清阴性接受者,其中供者CMV血清阳性318例、阴性695例。
  • 移植类型包括HLA相合同胞供者(采用钙调神经磷酸酶抑制剂为基础或移植后环磷酰胺为基础的移植物抗宿主病预防)及单倍体供者(采用移植后环磷酰胺)。
  • 研究采用多种常规与机器学习方法校正混杂因素。

主要发现

  • 在所有分析中,供者CMV血清阳性状态一致与显著较差的总生存(OS)和无病生存(DFS)相关,主要由非复发死亡率(NRM)增加驱动。
  • Cox比例风险模型中,供者CMV血清阳性与较差OS的风险约增加27%-33%相关,NRM约升高50%-60%。
  • 供者年龄较大在部分但非全部模型中与OS和DFS有统计学显著关联,Cox比例风险模型中约每年风险增加1%。
  • 机器学习模型揭示供者年龄存在更复杂细致的非线性效应,并进一步证实供者CMV血清阳性的不良影响。

临床怎么用

  • 作者认为,在CMV血清阴性接受者中优先选择CMV血清阴性供者可能与改善结局相关。
  • 作者指出需进一步研究验证这些发现并探索潜在机制。

局限性

  • 作者指出需进一步研究验证这些发现并探索潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus (CMV) infection post-hematopoietic cell transplantation (HCT) remains a significant cause of morbidity and mortality. While letermovir prophylaxis is available for CMV-seropositive recipients, optimal donor selection for CMV-seronegative recipients remains unclear, with donor age often prioritized over CMV serostatus. We investigated the relative impact of donor age and CMV serostatus in CMV-seronegative recipients (n = 1013) with either CMV-seropositive (n = 318) or CMV-seronegative donors (n = 695), who underwent HCT with HLA-matched sibling donors with calcineurin inhibitor-based or post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis, or haploidentical donors with PTCy. Multiple conventional and machine-learning approaches were employed to account for confounding factors. Across all analyses, CMV-seropositive donor status was consistently associated with significantly inferior overall survival (OS) and disease-free survival, primarily driven by increased non-relapse mortality (NRM). Older donor age showed a statistically significant association with OS and DFS in some but not all models, and its effect size was small (about 1% increased hazard per year in Cox proportional hazard model) compared to the substantial impact of CMV-seropositive donors (about 27%-33% increased hazards for worse OS, approximately 50%-60% higher NRM in Cox proportional hazard model). However, our machine learning model revealed a more nuanced and complex non-linear effect of donor age, further demonstrating the adverse impact of donor CMV serostatus. Our findings suggest that prioritizing a CMV-seronegative donor may be associated with improved outcomes in CMV-seronegative recipients. Further research is needed to validate these findings and explore underlying mechanisms.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mehta RS, Choe H, Saultz J, et al. Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. Am J Hematol. 2025. PMID: 40071498. doi:10.1002/ajh.27662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。